Immunoradiometric assay of myosin heavy chain fragments in plasma for investigation of myocardial infarction.
Estimation of the extent and location of infarct is important for the prognosis and hence therapeutic strategy in patients with acute myocardial infarction (AMI). Because cardiac myosin is the major structural protein of the myocardium, and may thus reflect the extent of injured tissue, we established a new sensitive immunoradiometric assay, using a pair of monoclonal antibodies (Mabs) that specifically bind the myosin heavy chain fragments liberated from the myocyte into plasma after a heart attack. A first Mab is linked to a magnetic solid phase. A second Mab, radiolabeled with 125I, is used to detect myosin trapped on the solid phase by the first Mab during a 3-h incubation. This assay can detect 10 micro-units of myosin per liter and is highly reproducible.
Larue
C
C
Sanofi Recherche, Montpellier, France.
Calzolari
C
C
Léger
J
J
Léger
J
J
Pau
B
B
D000911:Antibodies, Monoclonal; D006325:Heart Atria / Q000378:metabolism; D006352:Heart Ventricles / Q000378:metabolism; D006801:Humans; D015592:Immunoradiometric Assay / Q000592:standards / Q000706:statistics & numerical data; D007700:Kinetics; D008832:Microchemistry; D009203:Myocardial Infarction / Q000097:blood*; D009218:Myosins / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D011786:Quality Control; D011863:Radioimmunoassay
D000911:Antibodies, Monoclonal; D010446:Peptide Fragments; D009218:Myosins